CLVS Share Price

Open 54.91 Change Price %
High 55.04 1 Day -2.87 -5.21
Low 51.73 1 Week -2.81 -5.11
Close 52.17 1 Month -5.72 -9.88
Volume 1110688 1 Year 35.47 212.40
52 Week High 74.94
52 Week Low 11.57
CLVS Important Levels
Resistance 2 55.24
Resistance 1 53.97
Pivot 52.98
Support 1 50.37
Support 2 49.10
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
DCTH 0.02 0.00%
SUSQ 14.20 -0.77%
ASTI 0.00 0.00%
SIRI 5.29 3.32%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
NIHD 0.74 39.62%
NIHD 0.74 39.62%
WRES 0.09 28.57%
CGEI 0.28 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
AEZS 1.18 22.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
CLSN 0.23 -93.11%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Clovis Oncology, Inc. (NASDAQ: CLVS)

CLVS Technical Analysis 1.5
As on 26th May 2017 CLVS Share Price closed @ 52.17 and we RECOMMEND Buy for LONG-TERM with Stoploss of 40.93 & Sell for SHORT-TERM with Stoploss of 57.89 we also expect STOCK to react on Following IMPORTANT LEVELS.
CLVS Target for May
1st Target up-side 64
2nd Target up-side 68.28
3rd Target up-side 72.56
1st Target down-side 51.78
2nd Target down-side 47.5
3rd Target down-side 43.22
CLVS Other Details
Segment EQ
Market Capital 588133504.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.clovisoncology.com
CLVS Address
CLVS
2525 28th Street
Suite 100
Boulder, CO 80301
United States
Phone: 303-625-5000
Fax: 303-245-0360
CLVS Latest News
Interactive Technical Analysis Chart Clovis Oncology, Inc. ( CLVS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Clovis Oncology, Inc.
CLVS Business Profile
Clovis Oncology, Inc. (Clovis) is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.